CYC, page-14

Little AI generated comparison of the two...

Cyclopharm (ASX:CYC) and 4DMedical (ASX:4DX) are both innovators in lung imaging but approach the market with distinct technologies and focuses.

Cyclopharm - Technegas

Cyclopharm’s flagship product, Technegas, is a well-established nuclear medicine tool for pulmonary ventilation imaging. Its recent FDA approval for the U.S. market marks a significant milestone, allowing it to enter a large, untapped market worth approximately USD 180 million annually for pulmonary embolism diagnosis. Technegas is favored for its ability to provide detailed imaging compared to older technologies like Xenon-133 or wet aerosols, which suffer from limitations in energy and clarity. The product has been widely adopted in 64 countries, amassing over 4.7 million studies and proving its efficacy in conditions like pulmonary embolism, COPD, and potentially long COVID【28†source】【29†source】.

4DMedical - XV Technology

4DMedical, on the other hand, focuses on non-invasive imaging using its proprietary XV Technology, which leverages AI and computational models to provide detailed analysis of lung function. This technology does not rely on radioactive substances, offering an alternative for facilities aiming to minimize exposure risks. 4DMedical’s software-driven approach is marketed as a cost-effective and scalable solution for diagnosing and monitoring lung diseases such as asthma and COPD, with a strong emphasis on recurring revenue from software licensing【27†source】.

Key Comparisons:

1. Technology Basis:

   • Cyclopharm's Technegas relies on nuclear medicine, offering a proven diagnostic standard but requiring specialized infrastructure.
   • 4DMedical's solution is software-centric, potentially more accessible to facilities without nuclear medicine capabilities.

2. Market Focus:

   • Cyclopharm is targeting high-demand markets like the U.S. for conditions requiring nuclear imaging, such as pulmonary embolisms.
   • 4DMedical is broadening its utility across respiratory conditions with a focus on predictive analytics and real-time monitoring.

3. Revenue Models:

   • Cyclopharm generates annuity revenue from consumables associated with each Technegas procedure.
   • 4DMedical emphasizes software licensing, which provides recurring income from installations.

4. Growth Potential:

   • Cyclopharm has a head start with an established global footprint and regulatory approvals in key markets.
   • 4DMedical is building momentum with its innovative, radiation-free technology and scalable business model.

Both companies address critical needs in lung imaging, but their technologies cater to slightly different market segments and user needs. Cyclopharm is the established player expanding into untapped markets, while 4DMedical offers a next-generation alternative focusing on flexibility and AI-driven insights【28†source】【29†source】.